Page 2 of 3
PRIOR AUTHORIZATION PREFERRED DRUG LIST (PA/PDL) FOR ANTIEMETICS, CANNABINOIDS
F-00194 (11/09)
®
SECTION III B — CLINICAL INFORMATION FOR MARINOL
AND CESAMET (Continued)
16. Is there a clinically significant drug interaction between another medication
the member is taking and ondansetron?
Yes
No
If yes, list the other medication the member is taking and describe the clinically significant
drug interaction in the space provided.
17. Has the member experienced a clinically significant adverse drug reaction while taking
ondansetron?
Yes
No
If yes, describe the clinically significant adverse drug reaction in the space provided.
®
18. Has the member experienced a treatment failure with Emend
for chemotherapy-
related nausea and vomiting?
Yes
No
®
19. Does the member have a medical condition(s) preventing the use of Emend
?
Yes
No
®
If yes, list the medical condition(s) that prevents the use of Emend
in the space provided.
20. Is there a clinically significant drug interaction between another medication the
®
member is taking and Emend
?
Yes
No
If yes, list the other medication the member is taking and describe the clinically significant
drug interaction in the space provided.
21. Has the member experienced a clinically significant adverse drug reaction while
®
taking Emend
?
Yes
No
If yes, describe the clinically significant adverse drug reaction in the space provided.
SECTION III C — CLINICAL INFORMATION FOR CESAMET ONLY (Complete Section III B and Section III C for requests for
Cesamet.)
®
22. Has the member experienced a treatment failure with Marinol
for chemotherapy-
related nausea and vomiting?
Yes
No
Continued